Koers Bausch Health Companies Inc Nyse
Aandelen
CA91911K1021
Farmaceutische producten
Omzet 2024 * | 9,4 mld. 8,67 mld. | Omzet 2025 * | 9,67 mld. 8,92 mld. | Marktkapitalisatie | 2,4 mld. 2,22 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 148 mln. 137 mln. | Nettowinst (verlies) 2025 * | 389 mln. 359 mln. | EV/omzet 2024 * | 2,43 x |
Nettoschuld 2024 * | 20,44 mld. 18,86 mld. | Nettoschuld 2025 * | 19,09 mld. 17,62 mld. | EV/omzet 2025 * | 2,22 x |
K/w-verhouding 2024 * |
19,5
x | K/w-verhouding 2025 * |
6,22
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,62% |
Recentste transcriptie over Bausch Health Companies Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Appio
CEO | Chief Executive Officer | 61 | - |
John Barresi
DFI | Director of Finance/CFO | 51 | 24-05-22 |
Chief Operating Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Power
BRD | Director/Board Member | 67 | 01-08-08 |
John Paulson
CHM | Chairman | 68 | 01-06-17 |
Steven Miller
BRD | Director/Board Member | 35 | 17-03-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+37,63% | 723 mld. | |
+31,80% | 598 mld. | |
-2,53% | 364 mld. | |
+20,37% | 331 mld. | |
+3,40% | 288 mld. | |
+16,13% | 244 mld. | |
+9,79% | 210 mld. | |
-5,24% | 208 mld. | |
+8,63% | 169 mld. |